|
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Results Show MetAP2 Inhibitor Treatment Improves Cardiovascular Risk Markers in Severely Obese Subjects
Company Also Announces Initiation of Dose Escalation Trial in Obese Women
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
|
|
|
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
|
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
|
|
|
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
Findings Show MetAP2 Inhibition Treatment Drives Significant Weight Loss with Excellent Tolerability and Favorable Metabolic Effects
|
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
|
|
|
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
Data Show Treatment with MetAP2 Inhibitor Eliminates Excess Body Fat through Regulation of Fat Metabolism and Food Intake and Normalizes Glucose Tolerance in Preclinical Models
|
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
|
|
|
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
|
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
|
|
|
Summary ToggleZafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009
|
Summary ToggleZafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009
|
|
|
Summary ToggleZafgen, Inc. Announces Participation at XSITE 2009
|
Summary ToggleZafgen, Inc. Announces Participation at XSITE 2009
|
|
|
Summary ToggleAmerican Diabetes Association Awards Leaders in the Field
Researchers, clinicians and educators acknowledged for their accomplishments in diabetes
|
Summary ToggleAmerican Diabetes Association Awards Leaders in the Field
|
|
|
Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions
Zafgen Scientific Advisory Board Member and Pioneering Researcher Dr. Randy J. Seeley Underscores the Active Role of Adipose Vasculature in Metabolic Disease
|
Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions
|
|
|
Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention
|
Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention
|